StreetInsider.com News Articles

Form 8-K Helix Acquisition Corp. For: Aug 06

Wed, 06 Aug 2025 07:35:00 -0400

si-local-file:///var/storage/secattach/20250806/25154851.html

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Wed, 06 Aug 2025 07:33:00 -0400

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing
2^nd lowest redemption rate for a biotech de-SPAC transaction since 2022

Form 425 Helix Acquisition Corp. Filed by: Helix Acquisition Corp. II

Mon, 04 Aug 2025 16:47:00 -0400

si-local-file:///var/storage/secattach/20250804/25144044.html

Form 8-K Helix Acquisition Corp. For: Aug 04

Mon, 04 Aug 2025 16:46:00 -0400

si-local-file:///var/storage/secattach/20250804/25144028.html

Form 10-Q Helix Acquisition Corp. For: Jun 30

Fri, 01 Aug 2025 16:47:00 -0400

si-local-file:///var/storage/secattach/20250801/25137375.html

Form SCHEDULE 13G/A Helix Acquisition Corp. Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Wed, 30 Jul 2025 16:16:00 -0400

si-local-file:///var/storage/secattach/20250730/25122335.html

Form SCHEDULE 13G Helix Acquisition Corp. Filed by: Sculptor Capital LP

Thu, 24 Jul 2025 21:05:00 -0400

si-local-file:///var/storage/secattach/20250724/25096318.html

Form 424B3 Helix Acquisition Corp.

Tue, 22 Jul 2025 06:01:00 -0400

si-local-file:///var/storage/secattach/20250722/25077607.html

Form 425 Helix Acquisition Corp. Filed by: TheRas, Inc.

Mon, 21 Jul 2025 08:10:00 -0400

si-local-file:///var/storage/secattach/20250721/25073409.html

Form 425 Helix Acquisition Corp. Filed by: Helix Acquisition Corp. II

Fri, 11 Jul 2025 07:46:00 -0400

si-local-file:///var/storage/secattach/20250711/25041107.html

Helix Acquisition and BridgeBio Oncology receive SEC approval for merger

Fri, 11 Jul 2025 07:45:17 -0400

Helix Acquisition Corp. II (NASDAQ: HLXB) and BridgeBio Oncology Therapeutics announced that the U.S. Securities and Exchange Commission declared effective their registration statement for a proposed business combination.

The special purpose acquisition company will hold an extraordinary general meeting of shareholders on August 4, 2025, to vote on the merger. The proxy statement will be mailed to Helix shareholders of record as of June 30, 2025.

The companies expect the business combination to close in August 2025, subject to satisfaction of closing conditions. Upon completion, the combined company will be renamed BridgeBio Oncology Therapeutics.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing

Helix Acquisition and BridgeBio Oncology receive SEC approval for merger

Fri, 11 Jul 2025 07:45:17 -0400

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing

Helix Acquisition and BridgeBio Oncology receive SEC approval for merger

Fri, 11 Jul 2025 07:45:17 -0400

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing

Helix Acquisition and BridgeBio Oncology receive SEC approval for merger

Fri, 11 Jul 2025 07:45:17 -0400

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing

Form 8-K Helix Acquisition Corp. For: Jul 11

Fri, 11 Jul 2025 07:45:00 -0400

si-local-file:///var/storage/secattach/20250711/25041099.html

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Fri, 11 Jul 2025 07:43:00 -0400

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025

SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a special purpose acquisition company (“SPAC”) sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the “Registration Statement”), filed by Helix and BBOT, relating to the previously-announced business combination

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Fri, 11 Jul 2025 07:43:00 -0400

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Fri, 11 Jul 2025 07:43:00 -0400

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Fri, 11 Jul 2025 07:43:00 -0400

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Fri, 11 Jul 2025 07:43:00 -0400

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025